Compare KLXE & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KLXE | VERU |
|---|---|---|
| Founded | 2018 | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.8M | 39.8M |
| IPO Year | N/A | 1990 |
| Metric | KLXE | VERU |
|---|---|---|
| Price | $1.82 | $2.18 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $25.00 |
| AVG Volume (30 Days) | ★ 213.1K | 198.5K |
| Earning Date | 11-05-2025 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $645,200,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.46 | $2.10 |
| 52 Week High | $7.40 | $14.20 |
| Indicator | KLXE | VERU |
|---|---|---|
| Relative Strength Index (RSI) | 55.30 | 38.28 |
| Support Level | $1.49 | $2.10 |
| Resistance Level | $1.92 | $2.42 |
| Average True Range (ATR) | 0.13 | 0.18 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 67.35 | 16.98 |
KLX Energy Services Holdings Inc is a provider of completion, intervention and production services and products to the onshore oil and gas producing regions of the United States. It serves the companies engaged in the exploration and development of onshore conventional and unconventional oil and natural gas reserves. Its products and services offerings include surface facilities and equipment, pressure control services, wireline services, fishing services, and engineered products. The company's segments include Southwest; Rocky Mountains and Northeast/Mid-Con region. It derives maximum revenue from Northeast/Mid-Con region.
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.